Symptom burden & quality of life among patients receiving second-line treatment of metastatic colorectal cancer

BACKGROUND: Bevacizumab (B) and cetuximab (C) are both approved for use in the treatment of metastatic colorectal cancer (mCRC) in the second-line. We examined patient reported symptom burden during second-line treatment of mCRC. METHODS: Adult mCRC patients treated in the second-line setting with a...

Descripción completa

Detalles Bibliográficos
Autores principales: Walker, Mark S, Pharm, Elaine Yu, Kerr, Jiandong, Yim, Yeun Mi, Stepanski, Edward J, Schwartzberg, Lee S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3532189/
https://www.ncbi.nlm.nih.gov/pubmed/22716038
http://dx.doi.org/10.1186/1756-0500-5-314

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3532189/
https://www.ncbi.nlm.nih.gov/pubmed/22716038
http://dx.doi.org/10.1186/1756-0500-5-314

Ejemplares similares